Drug Trial Radar · NCT05800015
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
Aug 8, 2023
Primary completion
Jan 16, 2030
Study completion Dec 23, 2031
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Apr 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is for treating advanced NSCLC, in comparison with cemiplimab and chemotherapy. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) * How administering the study drugs might improve your quality of life
Conditions
- Non-small Cell Lung Cancer
Interventions
fianlimabDrug
Administered intravenously (IV) every 3 weeks (Q3W)
cemiplimabDrug
Administered IV Q3W
PemetrexedDrug
IV Infusion, Q3W
PaclitaxelDrug
IV Infusion, Q3W
CarboplatinDrug
IV Infusion, Q3W
CisplatinDrug
IV infusion, Q3W
PlaceboDrug
IV infusion, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) as assessed by blinded independent review committee (BICR) using RECIST 1.1Time frame: Up to 136 Weeks
- Overall Survival (OS)Time frame: Up to 5 years
Locations
76 sites in 10 countries. Site status is shown where the registry gives one.
Arizona Clinical Research Center
Tucson, Arizona
Yuma Regional Medical Center
Yuma, Arizona
The Oncology Institute of Hope & Innovation
Cerritos, California
Crosson Cancer Institute
Fullerton, California
St. Joseph Hospital Orange
Orange, California
Desert Hematology Oncology Medical Group Incorporated
Rancho Mirage, California
Emad Ibrahim, MD, Inc.
Redlands, California
PIH Health Hospital
Whittier, California
Rocky Mountain Regional VA Medical Center
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Clermont Oncology Center
Clermont, Florida
Miami Veterans Administration HealthCare System
Miami, Florida
Mid Florida Hematology and Oncology Center
Orange City, Florida
Tallahassee Memorial Healthcare
Tallahassee, Florida
University of Illinois
Chicago, Illinois
Northwest Oncology and Hematology
Rolling Meadows, Illinois
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana
Hattiesburg Clinic
Hattiesburg, Mississippi
Capital Health Hopewell Medical Center
Pennington, New Jersey
New Mexico Cancer Care Alliance
Albuquerque, New Mexico
NYU Langone Health Perlmutter Cancer Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Montefiore Medical Center
The Bronx, New York
Clinical Research Alliance Inc
Westbury, New York
Gabrail Cancer Center Research
Canton, Ohio
Thompson Cancer Survival Center (TCSC ) - Downtown
Knoxville, Tennessee
University of Tennessee Medical Center
Knoxville, Tennessee
University of Virginia Medical Center
Charlottesville, Virginia
Bon Secours Cancer Institute Richmond
Midlothian, Virginia
Macquarie University Health Science Center (MQ Health)
Macquarie Park, New South Wales, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Ballarat Regional Integrated Cancer Centre (BRICC)
Ballarat, Victoria, Australia
Bendigo Hospital
Bendigo, Victoria, Australia
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia
St John of God Murdoch Hospital
Murdoch, Western Australia, Australia
British Columbia Cancer Center-Kelowna
Kelowna, British Columbia, Canada
Hopital Cite de la Sante
Laval, Quebec, Canada
Israeli Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
Research Institute of Clinical Medicine
Tbilisi, Georgia
LTD New Hospitals
Tbilisi, Georgia
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.